2. Search Result
Search Result
Results for "

hepatic cholesterol synthesis

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Natural
Products

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0468
    Rebaudioside D
    1 Publications Verification

    		 FXR Acetyl-CoA Carboxylase Metabolic Disease
    Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D
  • HY-116290
    Zaragozic acid A
    1 Publications Verification

    Squalestatin S1

    		 Endogenous Metabolite Metabolic Disease
    Zaragozic acid A is a fungal metabolite that acts as a reversible competitive inhibitor of squalene synthase. Zaragozic acid A is an inhibitor of acute hepatic cholesterol synthesis in mouse (IC50 = 6 μM) .
    Zaragozic acid A
  • HY-153491
    Olezarsen

    ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx

    		 Apolipoprotein Cardiovascular Disease
    Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) is a GalNAc-modified antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .
    Olezarsen
  • HY-153491A
    Olezarsen sodium

    ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium

    		 Apolipoprotein Cardiovascular Disease
    Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) sodium is a GalNAc-modified antisense oligonucleotide. Olezarsen sodium binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen sodium reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen sodium is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .
    Olezarsen sodium
  • HY-142026
    Vitisin A

    (+)-Vitisin A

    		 Caspase ERK NF-κB Influenza Virus PAK LDLR PPAR PCSK9 Androgen Receptor Keap1-Nrf2 Monoamine Oxidase Cholinesterase (ChE) IKK Wnt β-catenin Reactive Oxygen Species (ROS) Apoptosis Cuproptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Vitisin A ((+)-Vitisin A) is an orally active natural product with multiple pharmacological activities including anti-inflammatory, anti-tumor, anti-oxidant, anti-pathogenic microorganism, hypoglycemic and lipid-regulating, anti-osteoporotic, neuroprotective and cardiovascular protective effects. Vitisin A exhibits inhibitory effects on human AChE and MAO-B with IC50 values of 1.29 µM and 4.94 µM, respectively. Vitisin A inhibits the ERK, MAPK, NF-κB, STAT1, HMGCR and TRAF6 pathways, downregulates the related phosphorylation and protein expression, while activates the Nrf2/HO-1 pathway and upregulates p21 expression. Vitisin A induces tumor cell apoptosis and cell cycle arrest, inhibits adipogenesis and lipid accumulation, while alleviates oxidative stress, suppresses inflammatory responses, blocks hepatic fibrosis, Cuproptosis and cholesterol synthesis, and increases the expression levels of central BDNF and TrkB. Vitisin A can be used in the research of tumors, infectious diseases, metabolic diseases, bone and joint diseases, liver diseases, skin injuries, as well as neurodegenerative and cognitive dysfunction-related diseases .
    Vitisin A
  • HY-11088
    PF-3052334

    		HMG-CoA Reductase (HMGCR) Metabolic Disease
    PF-3052334 is an orally active, hepatically selective HMG-CoA reductase inhibitor with an IC50 of 1.9 nM. PF-3052334 inhibits cholesterol synthesis, with IC50 values ​​of 0.9 and 730 nM in hepatocytes and muscle cells, respectively. PF-3052334 can be used to study hypercholesterolemia .
    PF-3052334
  • HY-W015467
    Pyridine-3-sulfonic acid

    Pyridine-3-sulphonic acid

    		 Drug Derivative Metabolic Disease
    Pyridine-3-sulfonic acid (Pyridine-3-sulphonic acid) is an orally active structural analog of Nicotine acid (HY-B0143). Pyridine-3-sulfonic acid significantly reduces hepatic cholesterol synthesis in rats but lacks cholesterol-lowering activity. Pyridine-3-sulfonic acid does not interfere with the metabolism of Nicotine acid .
    Pyridine-3-sulfonic acid
  • HY-127055
    Tiadenol

    		Apolipoprotein Metabolic Disease Endocrinology
    Tiadenol is an absorbable hypolipidemic agent. Tiadenol can effectively reduce triglycerides and decrease the level of apolipoprotein E in very low-density lipoproteins in hyperlipoproteinemia. Tiadenol causes hepatomegaly in rats and affects their hepatic lipid levels, cholesterol synthesis and absorption at high doses. Tiadenol can be used in the research of endocrine and metabolic diseases such as hyperlipidemia .
    Tiadenol
  • HY-N0468R
    Rebaudioside D (Standard)

    		Reference Standards Acetyl-CoA Carboxylase FXR Metabolic Disease
    Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D (Standard)
  • HY-119449
    Florantyrone

    Zanchol

    		 Others Inflammation/Immunology
    Florantyrone (Zanchol) is a bile-promoting agent. Florantyrone increases the volume of bile rather than the content of bile acids. Zanchol can stimulate the synthesis of cholesterol in the liver, significantly raising the plasma cholesterol level, increasing the weight of the liver, but has no significant effect on the synthesis of cholesterol in the intestine. Florantyrone can be used in research on biliary motility disorders .
    Florantyrone
  • HY-105281
    rel-(E)-BMY 21950 sodium

    		Drug Derivative Metabolic Disease
    rel-(E)-BMY 21950 sodium is the relative configuration of BMY 21950 (HY-105281A). BMY 21950 is an HMG-CoA reductase inhibitor. BMY 21950 inhibits hepatic cholesterol synthesis .
    rel-(E)-BMY 21950 sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: